JP2017536821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536821A5 JP2017536821A5 JP2017525625A JP2017525625A JP2017536821A5 JP 2017536821 A5 JP2017536821 A5 JP 2017536821A5 JP 2017525625 A JP2017525625 A JP 2017525625A JP 2017525625 A JP2017525625 A JP 2017525625A JP 2017536821 A5 JP2017536821 A5 JP 2017536821A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- isolated
- acid sequence
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108091008874 T cell receptors Proteins 0.000 claims 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 14
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000009843 Thyroglobulin Human genes 0.000 claims 2
- 108010034949 Thyroglobulin Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960002175 thyroglobulin Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000800133 Homo sapiens Thyroglobulin Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000047688 human TG Human genes 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079713P | 2014-11-14 | 2014-11-14 | |
| US62/079,713 | 2014-11-14 | ||
| PCT/US2015/060282 WO2016077525A2 (en) | 2014-11-14 | 2015-11-12 | Anti-human thyroglobulin t cell receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536821A JP2017536821A (ja) | 2017-12-14 |
| JP2017536821A5 true JP2017536821A5 (enExample) | 2018-12-20 |
| JP6666342B2 JP6666342B2 (ja) | 2020-03-13 |
Family
ID=54704113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525625A Active JP6666342B2 (ja) | 2014-11-14 | 2015-11-12 | 抗サイログロブリンｔ細胞レセプター |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10450372B2 (enExample) |
| EP (2) | EP3218404B1 (enExample) |
| JP (1) | JP6666342B2 (enExample) |
| AU (1) | AU2015346350C1 (enExample) |
| CA (1) | CA2967778C (enExample) |
| WO (1) | WO2016077525A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2967778C (en) * | 2014-11-14 | 2024-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-thyroglobulin t cell receptors |
| WO2019046818A1 (en) | 2017-09-01 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER |
| US12448429B2 (en) | 2019-03-06 | 2025-10-21 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| US20250277013A1 (en) * | 2022-05-04 | 2025-09-04 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | T cell receptor derived binding polypeptides |
| WO2024097652A2 (en) * | 2022-10-31 | 2024-05-10 | Legend Biotech Ireland Limited | Anti-kras t cell receptors and engineered cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4874845A (en) * | 1984-06-13 | 1989-10-17 | Massachusetts Institute Of Technology | T lymphocyte receptor subunit |
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| AU2012262520A1 (en) | 2011-05-27 | 2014-01-23 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| PL3126381T5 (pl) * | 2014-04-01 | 2022-05-23 | Biontech Cell&Gene Therapies Gmbh | Immunoreceptory specyficzne dla klaudyny-6 i epitopy komórek t |
| CA2967778C (en) * | 2014-11-14 | 2024-04-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-thyroglobulin t cell receptors |
-
2015
- 2015-11-12 CA CA2967778A patent/CA2967778C/en active Active
- 2015-11-12 US US15/524,869 patent/US10450372B2/en active Active
- 2015-11-12 AU AU2015346350A patent/AU2015346350C1/en active Active
- 2015-11-12 WO PCT/US2015/060282 patent/WO2016077525A2/en not_active Ceased
- 2015-11-12 EP EP15801054.6A patent/EP3218404B1/en active Active
- 2015-11-12 EP EP20208238.4A patent/EP3808770B1/en active Active
- 2015-11-12 JP JP2017525625A patent/JP6666342B2/ja active Active
-
2019
- 2019-09-27 US US16/586,310 patent/US11440956B2/en active Active
-
2022
- 2022-08-04 US US17/817,599 patent/US12275786B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| JP2018535647A5 (enExample) | ||
| JP2015525208A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| JP2018121657A5 (enExample) | ||
| JP2017536825A5 (enExample) | ||
| JP2019522490A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JP2020501532A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| JP2012518425A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2017536821A5 (enExample) | ||
| CN106029694A (zh) | 治疗性肽 | |
| JP2002521391A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2018512145A5 (enExample) | ||
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2011523550A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| CN105142668A (zh) | 治疗性肽 | |
| JP2010502183A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| JP2020519293A5 (enExample) | ||
| JP2005528914A5 (enExample) |